Related Experiment Video

Updated: Jul 11, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Androgen receptor modulation: lessons learned from beyond the prostate

Nima Sharifi1, William D Figg

  • 1Medical Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA. nima.sharifi@nih.gov

Cancer Biology & Therapy
|September 21, 2007
PubMed

Insights

A new compound degrades the androgen receptor (AR), offering a novel approach to treating prostate diseases like prostate cancer and benign prostatic hyperplasia (BPH) by targeting AR function.

Area of Science:

  • Oncology
  • Endocrinology
  • Molecular Biology

Background:

  • The androgen receptor (AR) is a key transcription factor in prostate cancer and benign prostatic hyperplasia (BPH).
  • Current treatments for prostate diseases, including medical castration and AR antagonists, face limitations like AR reactivation, leading to castrate-resistant prostate cancer.
  • AR modulation is crucial for managing these conditions, necessitating novel therapeutic strategies.

Purpose of the Study:

  • To explore a novel compound that degrades the androgen receptor (AR).
  • To investigate the potential of this AR-degrading compound for treating prostate diseases, including prostate cancer.

Main Methods:

  • Review of recent findings on a compound that degrades AR.
  • Examination of the compound's mechanism, including induction of AR dissociation from coactivators.
  • Biochemical analysis of the compound's action.

Main Results:

  • Identification of a compound capable of degrading the androgen receptor (AR).
  • Demonstration that the compound induces dissociation of AR from its coactivator.
  • Exploration of the compound's biochemical properties and potential therapeutic applications.

Conclusions:

  • A novel compound effectively degrades the androgen receptor (AR).
  • This AR-degrading compound and its mechanism may offer new therapeutic avenues for prostate cancer.
  • Further research into this compound's biochemistry could impact prostate disease treatment.

More Related Videos

Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses08:36

Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses

Published on: October 24, 2019

Related Concept Videos

Testosterone: Functions and Regulation01:26

Testosterone: Functions and Regulation

The intricate hormonal interplay essential for male reproductive health begins with the release of gonadotropin-releasing hormone (GnRH) by the hypothalamus. This hormone prompts the pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). LH targets the Leydig cells in the testes, stimulating them to produce and release testosterone. In concert with testosterone, FSH acts on the Sertoli cells within the seminiferous tubules to facilitate the release of...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Internal Receptors01:31

Internal Receptors

Many cellular signals are hydrophilic and therefore cannot pass through the plasma membrane. However, small or hydrophobic signaling molecules can cross the hydrophobic core of the plasma membrane and bind to internal, or intracellular, receptors that reside within the cell. Many mammalian steroid hormones use this mechanism of cell signaling, as does nitric oxide (NO) gas.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...